Management of Cancer Anemia

References

• Skillings JR, Roger-Melamed I, Nabholtz JM, et al. An epidemiological review of anaemia in cancer chemotherapy in Canada. Eur J Cancer 1995; 31 Suppl 5: abstr.
   Google Scholar
• Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997; 34, Suppl 2: 13–19.
   PubMed Web of Science ®Google Scholar
• Seguin Y, Yerna M, Loo M, Weber M, Fillet G. Erythropoiesis in multiple myeloma: defective red cells produc-tion due to inappropriate erythropoietin production. Br J Haematol 1992; 82: 648–653.
   PubMed Web of Science ®Google Scholar
• Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. A randomized double-blind place-bo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syn-dromes. Br J Haematol 1998; 103 (4): 1070-1074.
   Google Scholar
• Hellstrom-Lindberg E, Ahlgren T, Seguin Y, et al. Treatment of anemia in myelodysplastic syndromes with gran-ulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 1998; 92 (1): 68-75.
   Google Scholar
• Terpos E, Mougiou A, Kouraklis A, et al. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. Br J Haematol. 2002; 118 (1): 174–180.
   PubMed Web of Science ®Google Scholar
• Rizzo JD, Lichtin AE, Woolf SH, et al. Us of erythro-poietin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002; 20 (19): 4083–4107.
   PubMed Web of Science ®Google Scholar
• Alessandrino EP, Amadori S, Barosi G, et al. Evidence-and consensus-based practice guidelines for the therapy of pri-mary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica 2002; 87 (12): 1286–1306.
   PubMed Web of Science ®Google Scholar
• Gabrilove JL, Cleeland CS, Livingstone RB, Sarokan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dos-ing of epoetin alpha in chemotherapy patients: improvements in hemoglobina and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19: 2875–2882.
   PubMed Web of Science ®Google Scholar
• Egrie JC, Browne JK Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001; 84 Suppl.1: 3-10.
   PubMed Web of Science ®Google Scholar
• Smith RE Jr, Jaiyesimi IA, Meza LA, et al. Novel ery-thropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer. Br J Cancer. 2001; 84, Suppl.1: 24-30.
   Google Scholar
• Glaspy JA, Jadeja JS, Justice G, et al. Darbepoetin alpha given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 2002; 87 (3): 268–276.
   PubMed Web of Science ®Google Scholar
• Glaspy J, Jadeja J, Justice G et al. Randomized, active controlled, phase 1/2, dose escalation study of NESP admin-istered weekly and every 2 weeks in patients with solid tumors. Proc Am Soc Clin Oncol 2001; 20: 387a (abstr).
   Google Scholar
• Hedenus M, Adriansson M, San Miguel J, et al. Efficacy and safety of darbepoetin alpha in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003; 122 (3): 394–403.
   PubMed Web of Science ®Google Scholar
• Kotasek D, Steger G, Faught W, et al. Darbepoetin alpha administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 2003; 39 (14): 2026–2034.
   PubMed Web of Science ®Google Scholar
• Dougherty FC, Reigner B, Jordan P, Pannier A. CERA (continuous erythropoiesis receptor activator) demonstrates dose-dependent activity and is well tolerated in Phase I multi-ple ascending dose studies. Blood 2003; 102 (11): 204a (abs).
   Google Scholar
• Glaspy J, Bukowsky R, Steinberg D, et al. Impact of therapy with epoetin alpha on clinical outcomes in patients with non myeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997; 15: 1218–1234.
   PubMed Web of Science ®Google Scholar
• Leyland-Jones B, BEST Investigators and Study Group. Breast cancer trial with erythropoietin terminated unexpected-ly. Lancet Oncol 2003; 4 (8): 459–460.
   PubMed Web of Science ®Google Scholar
• Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anemia undergoing radiotherapy: randomised, double-blind, placebo controlled trial. Lancet 2003; 362: 1255–1260.
   PubMed Web of Science ®Google Scholar
• Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Epoetin alpha study group. Effects of epoetin alpha on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a ran-domized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19 (11): 2865–2874.
   Google Scholar
• Leyland-Jones B, O'Shaughnessy JA. Erythropoietin as a critical component of breast cancer therapy: survival, syner-gistic, and cognitive applications. Semin Oncol. 2003; 30, Suppl 16: 174–184.
   PubMed Web of Science ®Google Scholar
• Olsen NV. Central Nervous System frontiers for use of Erythropoietin C I D 2003; 37, Suppl 4: 323-330.
   Google Scholar
• Casadevall N. Pure red cell aplasia and anti-erythropoi-etin antibodies in patients treated with epoetin. Nephrol Dial Transplant. 2003; 18, Suppl 8: 37–41.
   Google Scholar